Biocon Limited — Investor Meet, 17-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon reported Q3 FY26 operating revenue up 9% to INR 4,173 Cr, fueled by strong Generics (+24%) and Biosimilars (+9%) despite CRDMO challenges. Core EBITDA grew 21% to INR 1,221 Cr (29% margin). The company has retired structured debt, strengthening its balance sheet and earning credit rating upgrades. With major capex largely completed, Biocon is set for sustainable growth, margin expansion, and cash flow generation. New biosimilar launches, including Yesintek in the U.S., show strong traction, and full global rights for Adalimumab (Hulio) have been secured. Management is confident in long-term value creation across its integrated portfolio.